COX2 regulation of breast cancer bone metastasis

OncoImmunology

Volumn 2, Issue 3, 2013, Pages

  Karavitis, John ^a   Zhang, Ming ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

EP2; EP4; Immunosuppression; Immunotherapy; Mammary tumor; Regulatory T cell

Indexed keywords

CASPASE 3; CD8 ANTIGEN; CYCLOOXYGENASE 2; INTERLEUKIN 10; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CELL DIFFERENTIATION; ENZYME REGULATION; HUMAN; IMMUNOPATHOLOGY; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL;

EID: 84886944419     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23129     Document Type: Article

References (10)

1. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24:5373-80; PMID:17135638; http://dx.doi.org/10.1200/JCO.2006.05.9584.
2. Howe LR. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 2007; 9:210; PMID:17640394; http://dx.doi.org/10.1186/bcr1678.
3. Karavitis J, Hix LM, Shi YH, Schultz RF, Khazaie K, Zhang M. Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration. PLoS One 2012; 7:e46342; PMID:23029485; http://dx.doi.org/10.1371/journal.pone.0046342.
4. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67:4507-13; PMID:17483367; http://dx.doi.org/10.1158/0008-5472.CAN-06-4174.
5. Yuan XL, Chen L, Li MX, Dong P, Xue J, Wang J, et al. Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2- dependent manner. Clin Immunol 2010; 134:277-88; PMID:19900843; http://dx.doi.org/10.1016/j.clim.2009.10.005.
6. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 2005; 65:5211-20; PMID:15958566; http://dx.doi.org/10.1158/0008-5472.CAN-05-0141.
7. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450:903-7; PMID:18026089; http://dx.doi.org/10.1038/nature06309.
8. Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M, et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 2010; 120:2030-9; PMID:20501944; http://dx.doi.org/10.1172/JCI42002.
9. Ménétrier-Caux C, Gobert M, Caux C. Differences in tumor regulatory T-cell localization and activation status impact patient outcome. Cancer Res 2009; 69:7895-8; PMID:19808962; http://dx.doi.org/10.1158/0008-5472.CAN-09-1642.
10. Li Z, Schem C, Shi YH, Medina D, Zhang M. Increased COX2 expression enhances tumor-induced osteoclastic lesions in breast cancer bone metastasis. Clin Exp Metastasis 2008; 25:389-400; PMID:17965942; http://dx.doi.org/10.1007/s10585-007-9117-3.